Skinvisible (SKVI) Selling, General & Administrative (2010 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -3.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 3.41 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -2.87 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 110.21 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 351.74 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 206.70 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 112,821.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 112,821.00 |
| Mar 31, 2026 | 125,931.00 |
| Dec 31, 2025 | 114,051.00 |
| Sep 30, 2025 | 105,939.00 |
| Jun 30, 2025 | 136,174.00 |
| Mar 31, 2025 | 139,912.00 |
| Dec 31, 2024 | 198,693.00 |
| Sep 30, 2024 | 124,032.00 |
| Jun 30, 2024 | 142,937.00 |
| Mar 31, 2024 | 123,489.00 |
| Dec 31, 2023 | 136,791.00 |
| Sep 30, 2023 | 113,570.00 |
| Jun 30, 2023 | 112,983.00 |
| Mar 31, 2023 | 128,260.00 |
| Dec 31, 2022 | 117,978.00 |
| Sep 30, 2022 | 128,454.00 |
| Jun 30, 2022 | 114,332.00 |
| Mar 31, 2022 | 133,418.00 |
| Dec 31, 2021 | 100,620.00 |
| Sep 30, 2021 | 114,578.00 |